Two examples of the Company’s speed advantage resulting from its internal innovation at scale: CDK4i entered the clinic in ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

That said, only 14% of drugs in clinical trials make it to FDA approval, according to Research from MIT, pushing the average ...

To better understand why some cancer patients struggle to fight off infections, Georgia Tech researchers have created tiny ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track ...

Scharffenberger then tested whether his dual-tipped, or “bispecific,” antibody could engage B cells with the correct genetic ...

Our synthetic hydrogels create a breakthrough environment for human immune organoids, allowing us to model antibody production from scratch, more precisely, and for a longer duration." Ankur Singh, ...